Clinical trials: Acute Schizophrenia
Schizophrenia
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
- Trial name
- NCT00694707
- Testing
- Cariprazine, Risperidone
- Where
- 65 sites in United States, India and 3 more
- Volunteers
- 732 people
- Sponsor
- Forest Laboratories
Schizophrenia
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
To assess the efficacy and safety of an investigational compound PF-02545920 for the treatment of schizophrenia. PF-02545920 will be more effective than placebo in reducing symptoms associated with schizophrenia.
- Trial name
- NCT00570063
- Testing
- PF-02545920
- Where
- 10 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pfizer
Schizophrenia, Mania
A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, acute mania, delusional disorder and…
- Conditions
- Schizophrenia, Mania, Delusional Disorder, Acute Exacerbation of Psychosis
- Trial name
- NCT00644800
- Testing
- Ziprasidone
- Where
- 8 sites in Brazil
- Volunteers
- 89 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorders
Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder
The purpose of this study is to determine whether increasing the amount (dose) of quetiapine IR (immediate release formulation) more rapidly than conventional dose increases, improves the control of symptoms as measured by the…
- Conditions
- Schizophrenia, Schizoaffective Disorders, Psychotic Disorders
- Trial name
- RAPID (NCT00457899)
- Testing
- Quetiapine IR (Immediate Release)
- Where
- 12 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- AstraZeneca
Schizophrenia
Acute Psychological Effects of High Intensity Exercise With Schizophrenia
The purpose of this study is to study the acute psychological effects in patients with schizophrenia after one session of high intensity exercise.
- Trial name
- NCT01310998
- Testing
- High intensity exercise
- Where
- Norway
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Schizophrenia, Psychotic Disorders
Acute Glycine Pharmacodynamic Study
The purpose of this study is to use proton magnetic resonance spectroscopy (MRS) at 4 Tesla to measure brain glycine levels noninvasively at baseline and for 2 hours after a single oral dose of a concentrated glycine-containing…
- Trial name
- NCT01610011
- Testing
- Glycine administration
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Schizophrenia
A Study of LY2140023 in Patients With Schizophrenia
The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as compared to placebo.
- Trial name
- NCT01307800
- Testing
- LY2140023
- Where
- 13 sites in United States, Mexico and 3 more
- Volunteers
- 567 people
- Sponsor
- Denovo Biopharma LLC
Acute Schizophrenia
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
The purpose of this study is to evaluate the efficacy of brexpiprazole compared with placebo as maintenance treatment in adults with schizophrenia.
- Trial name
- EQUATOR (NCT01668797)
- Testing
- Brexpiprazole
- Where
- 49 sites in United States, Colombia and 6 more
- Volunteers
- 524 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizotypal Disorder
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
The OPUS YOUNG (OY) study investigates the efficacy of early intervention service versus treatment as usual (TAU) for adolescents aged 12-17 years with a first-episode psychosis.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
- Trial name
- OPUS-YOUNG (NCT04916626)
- Testing
- OPUS YOUNG, Treatment as Usual
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Bipolar I Disorder, Bipolar II Disorder
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT07116694
- Testing
- BXCL501 Sublingual Film
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia
Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)
The purpose of this study is to assess whether SCH 900435 (Org 25935) 16 mg twice daily is more effective than placebo in the treatment of patients with schizophrenia, using olanzapine 15 mg once daily as active control.
- Trial name
- GUEST (NCT00988728)
- Testing
- SCH 900435 (Org 25935), Olanzapine
- Sponsor
- Merck Sharp & Dohme LLC
Acute Abstinence From Cigarettes vs E-cigarettes (ENDS)
Vaping and Smoking Project in People With Schizophrenia
The proposed research will characterize withdrawal among people with schizophrenia who vape daily compared to people with schizophrenia who smoke combustible cigarettes daily, filling critical gaps in the understanding of…
- Trial name
- VASP-S (NCT06944847)
- Testing
- Acute (24-hour) abstinence, Ad libitum smoking/vaping
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- State University of New York at Buffalo
Acute Pain, Chronic Pain, Widespread
Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain
This is a clinical trial that intend to determine the effects of S-ketamine on event-related potentials associated with semantic affective pain-processing
- Conditions
- Acute Pain, Chronic Pain, Widespread, Schizophrenia
- Trial name
- NCT03915938
- Testing
- Ketamine
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Schizophrenia
Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia
This is a phase 3, multicenter, randomized, active-controlled trial to assess the efficacy and safety of aripiprazole Intramuscular Depot in the acute treatment of adults with schizophrenia.
- Trial name
- NCT03172871
- Testing
- Aripiprazole IM Depot, Aripiprazole tablet
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
The primary purpose of this study is to evaluate the overall efficacy of aripiprazole intramuscular (IM) depot as acute treatment in subjects with schizophrenia.
- Trial name
- NCT01663532
- Testing
- Aripiprazole IM Depot
- Where
- 49 sites in United States, Croatia and 1 more
- Volunteers
- 340 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Acute Schizophrenia Episode
Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study
This study attempts to observe the effectiveness and safety of aripiprazole in hospitalized patients with acute schizophrenia episode, and to compare the different drug regimens that may be involved in order to clarify the…
- Trial name
- NCT03289026
- Testing
- Aripiprazole
- Where
- 12 sites in China
- Volunteers
- 770 people
- Sponsor
- Peking University